Health News Review

Stem cell news bites: Mesoblast, BioTime, MS, FDA Warning, & More

Mesoblast-stock

Stem cell studies continue to make big news with a mixed bag of trends, and some good stem cell news and others not so much. Mesoblast ($MESO) had its stock suspended for quite so time recently in anticipation of a big announcement. When that news came today it was discouraging in the form of its partner …

Stem cell news bites: Mesoblast, BioTime, MS, FDA Warning, & More Read More »

Science press releases behaving badly: time to start tracking their retractions?

Science-Press-Release-Retraction

Over at RetractionWatch, their team does a great job following retractions of science papers. Sadly, the number of published manuscript retractions gives them more than enough material to post several times a day. There’s another phenomenon going on that I think might warrant their increased attention: the possibly rising number of retractions or corrections of science …

Science press releases behaving badly: time to start tracking their retractions? Read More »